Summit to Present Clinical and Biomarker Programmes for DMD at WMS Congress

Accessibility: Skip TopNav

September 30, 2013 07:00 ET

Summit Therapeutics plc

Summit Therapeutics plc

Summit Corporation plc

('Summit' or 'the Company')

SUMMIT TO PRESENT CLINICAL AND BIOMARKER DEVELOPMENT PROGRAMMES FOR DMD AT THE 18th INTERNATIONAL WORLD MUSCLE SOCIETY CONGRESS

Oxford, UK, 30 September 2013 - Summit (AIM: SUMM), a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy ('DMD') and C. difficile infection, will present a summary of the clinical and biomarker programmes for its oral utrophin modulator SMT C1100 for the treatment of DMD at the 18th International World Muscle Society Congress meeting in Asilomar, California, USA from 1-5 October 2013.

The poster presentation entitled "Future clinical and biomarker development for SMT C1100, the first utrophin modulator to enter clinical trials for Duchenne Muscular Dystrophy" will outline the proposed clinical development plan to achieve proof of concept for SMT C1100 in DMD patients.  Details will also be presented on the supporting biomarker programme that aims to develop new exploratory clinical endpoints to help evaluate the benefit of therapies such as SMT C1100 in future DMD patient trials.

The presentation will be part of the "Dystrophinopathies: Imaging and biomarkers" session that will be held at 16:30 PST on Friday, 4 October.  A copy of the presentation will be available on the Company's website, www.summitplc.com from Wednesday, 2 October 2013.

Summit is an Oxford, UK based drug discovery and development Company targeting high-value areas of unmet medical need including Duchenne Muscular Dystrophy and C. difficile infection.  Summit is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM. Further information is available at www.summitplc.com and follow Summit on Twitter (@summitplc).

For more information, please contact:

Forward Looking Statements

This announcement contains "forward-looking statements", including, but not limited to, statements about the discovery, development and commercialisation of programme assets. These forward-looking statements are statements based on the Company's current intentions, beliefs and expectations, which include, among other things, the Company's results of operations, financial condition, prospects, growth, strategies and the industry in which the Company operates. No forward-looking statement is a guarantee of future performance and actual results could differ materially from those expressed or implied in the forward-looking statements. Accordingly, readers should not place undue reliance on forward-looking statements or information.  Forward-looking statements and information by their nature involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements or information. These include but are not limited to: adverse results in clinical or preclinical development studies; delays in obtaining regulatory approval; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; being unable to secure partnership agreements to develop and commercialise programme assets; being unable to secure the necessary funding to conduct any proposed research and development studies; and the ability to retain and recruit key personnel.  The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement contained in this announcement to reflect any changes in expectations with regard thereto or any changes in events, conditions or circumstances on which any such statement is based, except as required by applicable law.